This bill mandates that health benefit plans in Arkansas provide coverage for monoclonal antibodies used for the immunization of infants against respiratory syncytial virus (RSV) disease, effective January 1, 2026. The legislation defines a "health benefit plan" and outlines the types of plans that are included and excluded from this requirement. Notably, the coverage for these monoclonal antibodies will not be subject to annual deductibles, copayments, or coinsurance limits, ensuring that infants receive this critical immunization without additional financial barriers.

Additionally, the bill establishes a framework for the implementation of these provisions, assigning the Insurance Commissioner, the Secretary of the Department of Human Services, and the State Board of Finance the responsibility to promulgate necessary rules. These rules must be filed with the Secretary of State and the Legislative Council by January 1, 2026, to ensure timely adoption and compliance with the new coverage requirements.